Open AccessEfficacy of Equoral in Prophylactic Immunosuppression after De Novo Kidney Transplantation
Author(s) -
Zadražil Josef,
Jabry Sadek Al,
Horák Pavel,
Bachleda Petr,
Gibejová Agata,
Kamarád Vojtěch
Publication year - 2007
Publication title -
dialysis & transplantation
Language(s) - English
Resource type - Journals
eISSN - 1932-6920
pISSN - 0090-2934
DOI - 10.1002/dat.20172
Subject(s) - medicine , immunosuppression , calcineurin , creatinine , urology , transplantation , prednisone , renal function , adverse effect , kidney transplantation , kidney , surgery
Abstract BACKGROUND Cyclosporin A is a well‐known calcineurin inhibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this study was to evaluate the efficacy and safety of a new generic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant recipients. METHODS Twenty cadaveric‐donor renal transplant recipients between 23 and 71 years of age at the time of transplantation (mean age 52 ± 12.5 years) were followed for 12 months to determine if the grafts functioned and if there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and prednisone (Prednison). RESULTS Mean serum creatinine level decreased significantly after transplantation. In 6 of the 20 patients observed, 7 biopsies showed acute rejection episodes (35%). Over the 12‐month post‐transplant period, all patients showed stable graft function, with a mean serum creatinine level of 202.1 ± 130.9 μmol/L. Patient and renal graft survival rates were 100% after 12 months. Most of the observed adverse events were those commonly reported with the use of cyclosporin, and they resolved with a reduction in the cyclosporin dose. Equoral treatment demonstrated an acceptable safety profile with maintenance of satisfactory and stable renal function. CONCLUSIONS Equoral as a primary immunosuppressant for de novo kidney transplant recipients seems effective and safe in terms of acute rejection rate, patient and renal graft survival rates, and side effect profiles.